Arindam Talukdar , Ph.D.

Senior Principal Scientist
Organic & Medicinal Chemistry
details-banner

Research Interest

Our lab aims to answer fundamental questions that lie at the interface of chemistry and biology by integrating the concept of organic chemistry, biochemistry and molecular modeling to perform structure-based design and synthesis of novel chemical entity to unravel the molecular mechanism and develop potential treatment for human diseases.

Probing Endosomal Toll-like Receptors (TLRs). TLRs are members of the larger family of evolutionarily conserved pattern recognition receptors which are critical first line of defence for self-nonself discrimination by the host immune response. Aberrant endosomal TLR activation is implicated in autoreactive inflammation in different autoimmune diseases. The goal is to rationally design selective inhibitors for the nucleic acid-recognizing TLRs for devising novel therapeutic strategies in relevant clinical contexts. 

Epigenetic modifying enzymes as novel therapeutic targets: The main focus is to perform structure-based design and synthesis of small-molecule regulators of epigenetics modifying enzymes such as histone methyltransferases (HMT) as tools to unravel the complex biology of epigenetics and contribute towards epigenetic-based drugs for the treatment of a number of diseases such as cancer, autoimmunity, diabetes, or neurological disorders.

Designing of Small molecules Topoisomerase 1 poison:

Topoisomerases are enzymes that participate in the overwinding or underwinding of DNA. The winding problem of DNA arises due to the intertwined nature of its double-helical structure. DNA becomes overwound ahead of a replication fork. If left unabated, this torsion would eventually stop the ability of DNA or RNA polymerases involved in these processes to continue down the DNA structure. Due to the presence of topoisomerase, this topological problem is solved and cell proliferation runs continuously. So, our structure based designing and synthesis of small molecules is so rational to inhibit the topoisomerase for unwinding the overwound.

Credentials

  • Senior Research Scientist (2010-2012), Albany Molecular Research Inc. Singapore
  • Post-doctoral Research Associate (2005-2009), Purdue University, USA (Prof. Mark Cushman).
  • Post-doctoral Research Scholar (2004-2005), The Ohio State University, USA (Prof. Peng George Wang).
  • M.Pharmacy (1997) Medicinal Chemistry, Panjab University, Chandigarh, India (Prof. Tilak Raj Juneja).

Patents & Publications

PATENTS:

  • Preparation of Quinazolinediones and use Thereof for Treatment of Non-Alcoholic Fatty Liver Disease. 202111061087. Filing date 25.12.2021.  
  • Quinazolinones Derivatives for Treatment of Non-Alcoholic Fatty Liver Disease, Preparation And Use Thereof.  PCT/IN2021/050621.
  • Bicycle Topoisomerase I Inhibiting Compounds, Process For Preparation And Use Thereof. WO2019229765.  
  • Purine Based Compounds As Toll-Like Receptor 9 Antagonist. WO/2019/092739, US 2020/034706. 
  • Bicyclic Compound and Use Thereof for Inhibiting SUV39H2. PCT/US2016/0051350. 
  • Blocking toll-like receptor 9 signaling with small molecule antagonist. WO2017/163264A1, US10662177B2. 
  • Preparation of 2,5-disubstituted pyrrolidines and tetrahydrothiophenes as leukotrine biosynthesis inhibitors. WO2000001670 A1, EP 1115702. 

 

PUBLICATIONS:

    1. Sarkar D, Chowdhury S, Goon S, Sen A, Dastidar UG, Mondal MA, Chakrabarti P*, Arindam Talukdar*. Discovery and Development of Quinazolinones and Quinazolinediones for Ameliorating Nonalcoholic Fatty Liver Disease (NAFLD) by Modulating COP1-ATGL Axis. Journal of Medicinal Chemistry, 2023, 66, 24, 16728. https://doi.org/10.1021/acs.jmedchem.3c01431   

 

  1. Arindam Talukdar*, Sarkar D. Catalyzing the Future of Medicinal Chemistry Research in India. Journal of Medicinal Chemistry (Editorial), 2023, 66, 16, 10868. https://doi.org/10.1021/acs.jmedchem.3c01304.